(Q44006878)

English

Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus

scientific article published in June 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

atherosclerosis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Joanne T Van

1

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Jianqiu Pan

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Talat Wasty

3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Eve Chan

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Xiaoshan Wu

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

M Arthur Charles

6

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

language of work or name

0 references

publication date

1 June 2002

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

89

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1306-1308

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902333-0

7 January 2021

Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902333-0

7 January 2021

Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902333-0

7 January 2021

Troglitazone and small low-density lipoprotein in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902333-0

7 January 2021

Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902333-0

7 January 2021

Effect of fluvastatin on low-density lipoprotein peak particle diameter.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902333-0

7 January 2021

The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902333-0

7 January 2021

Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902333-0

7 January 2021

Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902333-0

7 January 2021

Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902333-0

7 January 2021

Mechanism of action of niacin on lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902333-0

7 January 2021

Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902333-0

7 January 2021

Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902333-0

7 January 2021

Lipoprotein heterogeneity and apolipoprotein B metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902333-0

7 January 2021

Identifiers

10.1016/S0002-9149(02)02333-0

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44006878&oldid=2105585051"